Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Current Deferred Revenue (2016 - 2025)

Dexcom has reported Current Deferred Revenue over the past 16 years, most recently at $2.9 million for Q3 2025.

  • Quarterly Current Deferred Revenue fell 79.14% to $2.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Sep 2025, down 79.14% year-over-year, with the annual reading at $8.0 million for FY2024, 56.52% down from the prior year.
  • Current Deferred Revenue was $2.9 million for Q3 2025 at Dexcom, down from $6.1 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $18.4 million in Q4 2023 and troughed at $1.8 million in Q2 2021.
  • The 5-year median for Current Deferred Revenue is $7.8 million (2025), against an average of $7.5 million.
  • Year-over-year, Current Deferred Revenue soared 380.95% in 2022 and then plummeted 79.14% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.1 million in 2021, then soared by 380.95% to $10.1 million in 2022, then soared by 82.18% to $18.4 million in 2023, then tumbled by 56.52% to $8.0 million in 2024, then plummeted by 63.75% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Current Deferred Revenue are $2.9 million (Q3 2025), $6.1 million (Q2 2025), and $7.8 million (Q1 2025).